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Solute carrier family 22 member 18 antisense
S100A8/A9
Neuroplastin
A B S T R A C T
Our recent study revealed an important role of the neuroplastin (NPTN)β downstream signal in lung cancer
dissemination in the lung. The molecular mechanism of the signal pathway downstream of NPTNβ is a serial
activation of the key molecules we identified: tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2)
adaptor, nuclear factor (NF)IA/NFIB heterodimer transcription factor, and SAM pointed-domain containing ETS
transcription factor (SPDEF). The question of how dissemination is controlled by SPDEF under the activated
NPTNβ has not been answered. Here, we show that the NPTNβ-SPDEF-mediated induction of solute carrier
family 22 member 18 antisense (SLC22A18AS) is definitely required for the epithelial-mesenchymal transition
(EMT) through the NPTNβ pathway in lung cancer cells. In vitro, the induced EMT is linked to the acquisition of
active cellular motility but not growth, and this is correlated with highly disseminative tumor progression in vivo.
The publicly available data also show the poor survival of SLC22A18AS-overexpressing lung cancer patients.
Taken together, these data highlight a crucial role of SLC22A18AS in lung cancer dissemination, which provides
novel input of this molecule to the signal cascade of NPTNβ. Our findings contribute to a better understanding of
NPTNβ-mediated lung cancer metastasis.
1. Introduction
Cancer metastasis is a grave problem for cancer patients because of
its life-threatening nature, which may involve multiple-organ dys-
function due to the disseminated cancer’ growth. To overcome the
problem of the ability of cancer cells to metastasize, a mechanistic
understanding of cancer metastasis is necessary. The ‘seed and soil’
theory that was first proposed by Paget et al., in 1989 [1] may provide
critical clues regarding the complex mechanism of distant cancer me-
tastasis. In that theory, the term ‘seed’ indicates the cancer cells and
‘soil’ represents the favored organ of the cancer for the destination of
metastasis. The seed and soil theory has not been solved at the mole-
cular level. Hiratsuka et al. made a breakthrough in 2006–2008 by
identifying the relationship between the heterodimic calcium-binding
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protein S100A8/A9 and Toll-like receptor 4 (TLR4) [2,3].
A major metastatic destination of cancer is the lung. The lung senses
distant cancer cells and then secretes an abundant amount of S100A8/
A9, which in turn attracts distant cancer cells through their surface
TLR4. Saha et al. demonstrated that receptor for advanced glycation
end-products (RAGE) on the surface of cancer cells also functions as an
S100A8/A9-sensing receptor [4]. In addition to TLR4 and RAGE, we
succeeded in identifying four novel S100A8/A9 receptors: melanoma
cell adhesion molecule (MCAM), activated leukocyte cell adhesion
molecule (ALCAM) [5], extracellular matrix metalloproteinase inducer
(EMMPRIN) [6], and neuroplastin (NPTN)β (Suppl. Fig. S1) [7]. These
receptors seem to be differently expressed depending on the cancer
species, and their expression seems to be upregulated in response to the
progression of cancer malignancy.
Among these receptors, we reported a crucial role of an S00A8/A9-
NPTNβ axis in the progression of the dissemination of lung cancer in
vitro and in vivo [8] (Suppl. Fig. S2). Our homology research identified
NPTNβ as one of the novel S100A8/A9 receptors on the basis of the
cytoplasmic tail of EMMPRIN [7]. We later observed that the re-
lationship between EMMPRIN and NPTNβ is a paralog. NPTNβ is a type
I transmembrane protein that belongs to the Ig superfamily (Suppl. Fig.
S1); it is highly expressed in neuronal cells [9] and has functions in cell
adhesion [10] and the promotion of synaptic activity [11] and plasticity
[12]. NPTNβ is also expressed at a significant level in lung cancer cells,
and NPTNβ plays a crucial role in its disseminative progression when it
functions as a receptor to the extracellular S100A8/A9 [8]. What
downstream signal(s) does this axis use as a driving force for cancer
progression in the lung? We discovered a key transcription factor, nu-
clear factor (NF)IA/NFIB, which is positively regulated mostly by tumor
necrosis factor (TNF) receptor-associated factor 2 (TRAF2), but the
growth factor receptor bound protein 2 (GRB2)-RAS pathway also
contributes to the activation of NFIA/NFIB in an orchestrated manner
with TRAF2. The activation of NFIA/NFIB then leads to an induction of
SAM pointed domain containing ETS (SPDEF) transcription factor,
which greatly contributes to lung cancer progression with disseminative
activities (Suppl. Fig. S2).
Taken together, our data support the notion that the newly identi-
fied NPTNβ signaling pathway that is initiated by cancer surrounding
extracellular S100A8/A9 worsens the disseminating progression of lung
cancers. However, it remained to be addressed how an S100A8/A9-
NPTNβ signal that led to SPDEF activation might control the upregu-
lation of lung cancer dissemination. We conducted the present study to
investigate this in the context of lung cancer, toward the goal of un-
covering the signal pathway of NPTNβ.
2. Materials and methods
2.1. Cell lines
The cell lines used were as follows: HEK293T (a human embryonic
kidney cell line stably expressing the SV40 large T antigen; RIKEN
BioResource Center, Tsukuba, Japan) and A549 (a human lung ade-
nocarcinoma cell line with KRAS-mutant [G12S]; ATCC, Rockville,
MD). These cells were all cultivated in D/F medium (ThermoFisher
Scientific, Waltham, MA) supplemented with 10% fetal bovine serum
(FBS).
2.2. RNA-seq and quantitative real-time PCR
Total RNA was extracted from the cells with ISOGEN (Nippon Gene,
Tokyo) according to the manufacturer's instructions. The isolated RNA
was subjected to an RNA-seq-based analysis of gene expression
(Bioengineering Lab, Kanagawa, Japan). A real-time reverse transcrip-
tion-polymerase chain reaction (RT-PCR) was performed in a
LightCycler rapid thermal cycler system (Roche Diagnostics,
Indianapolis, IN) using a LightCycler 480 SYBR Green I Master Kit
(Roche Diagnostics) according to the manufacturer's instructions.
The forward and reverse primer pairs used (5′ to 3′) were as follows:
FGFR4 (forward: gccgtcaagatgctcaaag [Tm = 58 °C], reverse: gat-
cagcttcatcacctccat [Tm = 59 °C]), IGFBP2 (forward: ccaa-
gaagctgcgaccac [Tm = 60 °C], reverse: ggagtagaggtgctccagagg
[Tm = 62 °C]), ITGA1 (forward: cacatgtaaagttggatatcccttc
[Tm = 59 °C], reverse: ggtcacattttccatgagatagg [Tm = 58 °C]), ITGB4
(forward: ggagtaccagctgctgaacg [Tm = 62 °C], reverse: cggaa-
cacgtaggagtggtt [Tm = 61 °C]), KLF5 (forward: cgcatccactactgcgatta
[Tm = 59 °C], reverse: tgtgagtcctcaggtgagctt [Tm = 62 °C]),
SLC22A18AS (forward: gcttggtggttctctcctgat [Tm = 61 °C], reverse:
agtccttctgcgccctct [Tm = 62 °C]), SLC22A18 (Forward: catcttgcttacc-
tacgtgctg [Tm = 60 °C], reverse: cccagtttccgagacaggta [Tm = 60 °C]),
CDH1 (forward: cttactgcccccagaggat [Tm = 60 °C], reverse:
gctggctcaagtcaaagtcc [Tm = 60 °C]), CDH2 (forward: aatggatgaaa-
gacccatccac [Tm = 60 °C], reverse: gagccactgccttcatagtcaa
[Tm = 61 °C]), VIM (forward: gaccagctaaccaacgacaaa [Tm = 60 °C],
Reverse: gaagcatctcctcctgcaat [Tm = 59 °C]), ZEB1 (forward: ggag-
gatgacacaggaaagg [Tm = 59 °C], reverse: tctgcatctgactcgcattc
[Tm = 59 °C]), ZEB2 (forward: aggagctgtctcgccttg [Tm = 60 °C],
Reverse: ggcaaaagcatctggagttc [Tm = 58 °C]), SNAIL1 (forward:
gctgcaggactctaatccaga [Tm = 60 °C], reverse: atctccggaggtgggatg
[Tm = 59 °C]), SNAIL2 (forward: acagcgaactggacacacat [Tm = 61 °C],
reverse: gatggggctgtatgctcct [Tm = 60 °C]), TBP (forward: gaa-
catcatggatcagaacaaca [Tm = 58 °C], reverse: atagggattccgggagtcat
[Tm = 59 °C]). The TBP gene expression was used as a reliable cali-
bration control.
2.3. Plasmids and A549 cell-originated clones
The pIDT-SMART (C-TSC) vector, abbreviated as pCMViR-TSC [13],
was used for the transient expression of foreign genes. The cDNAs of
green fluorescence protein (GFP), human SLC22A18 sense, and its re-
verse sequence as SLC22A18AS were inserted into the multi-cloning site
of the pCMViR-TSC vector. The cells were transiently transfected with
the plasmid vectors using FuGENE-HD (Promega, Madison, WI). We
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established A549-originated clones (A549-GFP and A549-NPTNβ,
Fig. 1) that permanently express control GFP and NPTNβ [8] and clones
(AS#1 and AS#3) that express SLC22A18AS in a stable manner by a
convenient electroporation gene delivery method using pSAKA-4B
[8,14,15] and subsequent selection with puromycin at 20 μg/ml.
2.4. Cell growth and motility assays
We used the CellTiter 96® AQueous One Solution Cell Proliferation
Assay (MTS) (Promega) for the assessment of cell proliferation.
Migration and invasion assays were performed by the Boyden chamber
method. For the invasion assay, 8-μm-pore filters set in Transwell cul-
ture inserts (BD Biosciences) were coated with Matrigel. Cells
(3 × 104 cells/insert) were placed in the upper chamber in a low-serum
medium, D/F (0.5% FBS), and the lower chamber was filled with a
high-serum medium, D/F (10% FBS). Twelve hr later, the cells that had
passed through the membrane were stained with hematoxylin and eosin
(H&E) (Muto Pure Chemicals, Tokyo). Each Transwell insert was mi-
croscopically imaged in five distinct regions at 100 × magnification in
triplicate. The numbers of cells that had migrated to the five non-
overlapping regions were counted using BZ-analysis software (Keyence,
Osaka, Japan) and summed as the total cell number and are presented
as the average of three independent experiments.
2.5. In vivo mouse study
Seven-week-old female nude mice, i.e., BALB/c-nu/nu mice, were
purchased from CLEA Japan (Tokyo). All mice were provided with
sterilized food and water and were housed in a barrier facility under a
12:12-hr light/dark cycle. A549 cells and their derivative clone AS#3
(5 × 105 cells with Matrigel/50 μl/mouse) were directly injected with a
syringe (30-gauge needle) into the lungs of three mice per one group in
total two groups (3 mice/A549 cells; 3 mice/clone AS#3 cells), re-
spectively, under isoflurane anesthesia. The needle was inserted ap-
prox. 0.5 cm deep from the surface of the mouse's chest. One important
parameter to judge the successful injection to the inside of a mouse lung
is the feeling of slight pressure during the injection procedure.
Isoflurane was used at concentrations of 4%–5% for the induction and
2%–3% for the maintenance of anesthesia. At 1 month after the injec-
tion, the whole lungs were isolated and observed macroscopically, and
the disseminated cell-derived tumor foci> 1 mm in dia. were counted.
2.6. Image acquisition
Phase contrast images of the cultured cells were acquired using BZ-
X700 all-in-one fluorescence microscope (Keyence). Imaging mode,
phase contrast (focal distance 35 mm); magnification, x 200; pixel re-
solution, 960 × 720. The dissected mouse lung images were captured
using an iPhone 7 (Apple, Cupertino, CA). Imaging mode, digital
Fig. 1. RNA-seq based analysis. A: A func-
tional enrichment analysis (p< 0.05) was per-
formed for protein-coding RNAs in
GAD_DISEASE_CLASS with upregulated and
downregulated genes in the A549-derived
NPTNβ-overexpressing clone in a comparison
with those in the GFP-overexpressing clone. B:
Heat map for the selected genes that are upre-
gulated and downregulated in the cancer cate-
gory of the disease clustering as indicated in
panel (A). The analysis was performed using the
database for annotation, visualization and in-
tegrated discovery (DAVID) v6.8 (http://david.
ncifcr.gov/). C: A quantitative real-time PCR
analysis was carried out in the indicated cells on
the x-axis for the genes checked in red in panel
(B). The relative expression level of each sample
is shown after calibration with TBP gene (a
suitable housekeeping gene) value. Data are
mean ± SD. ***p< 0.001. (For interpretation
of the references to color in this figure legend,
the reader is referred to the Web version of this
article.)
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camera; magnification, x 1; pixel resolution, 4032 × 3024. The ac-
quired images were then edited using Microsoft Suite software
(cropped, contrast +0, brightness +20).
2.7. Statistical analyses
All values are expressed as the mean ± SD. All data were analyzed
by unpaired Student's t-test for significant differences between the
mean values of each group.
3. Results and discussion
For the comprehensive investigation of NPTNβ-regulated genes, we
performed an RNA-seq-based analysis, and this was followed by the
appearance of several genes with differing expressions between the
GFP-expressed control A549 cells and their NPTNβ-overexpressed
counterparts. We classified the altered genes into their disease cate-
gories (Fig. 1A), and the collected genes in the CANCER category
(Fig. 1B) and in the other categories (Suppl. figS3Figs. S3A–F) are
displayed as heat map lists. Regarding the genes on the CANCER list, we
searched for each individual gene in the literature. We were curious
about upregulated genes, especially the following six genes since they
might play an important part in cancer aggressiveness.
(1) Fibroblast growth factor receptor 4 (FGFR4) has been shown to
promote tumor invasion by coupling with FGF signaling [16]. (2) In-
sulin-like growth factor binding protein 2 (IGFBP2) acts as a potent
oncogene to drive cancer metastasis [17] with an epithelial-mesench-
ymal transition (EMT) [18]. (3) Integrin subunit alpha 1 (ITGA1) and
Fig. 2. The SLC22A18AS-mediated
upregulation of cellular motility. A:
A quantitative real-time PCR analysis of
SLC22A18AS gene was performed in
the cells that were transiently over-
expressed with either GFP or SPDEF. B:
A quantitative real-time PCR analysis
for SLC22A18AS (Antisense: AS) and
SLC22A18 (Sense: S) genes was per-
formed in the cells that were tran-
siently overexpressed with either GFP
or SLC22A18AS (AS). C: A549 cells
were transiently transfected with GFP
as a control, SLC22A18 (S), or
SLC22A18AS (AS) expression vector for
24 h. The cell growth of each sample
was evaluated by an MTS assay (left).
The migration (middle) and invasion
(right) of A549 cells transfected with
the indicated gene for 24 h were also
assessed by the Boyden chamber
method. The transfected A549 cells
were placed in the top chamber and
kept for 12 h. Migrated/invaded cells
were quantified by cell counting in five
non-overlapping fields at × 100 mag-
nification and are presented as the
average of three independent experi-
ments. D: The stably expressed clones
for the indicated genes (GFP or
SLC22A18AS, which corresponds to
clones AS#1 and AS#3) were assessed
for growth (left), migration (middle),
and invasion (right) according to the
same methods as described in (C). Data
are mean ± SD. *p< 0.05,
**p<0.01, ***p< 0.001. E: Images of
the indicated cells were obtained by
phase-contrast microscopy. Scales:
200 μm.
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(4) integrin subunit beta 4 (ITGB4) are members of an integrin super-
family that acts to attach to various types of extracellular matrixes in
various types of integrin complex between alpha and beta. It was re-
ported that upregulated ITGA1 enhances the metastatic potential in
pancreatic cancer cells [19], and that elevated ITGB4 promoted the
metastasis of gastric cancer [20] and hepatocellular carcinoma [21]. (5)
Kruppel-like factor 5 (KLF5) is a transcription factor that can promote
cancer proliferation, migration, and invasion via the upregulation of its
several targeted oncogenic genes [22,23]. Lastly, (6) solute carrier fa-
mily 22 member 18 antisense (SLS22A18AS) is also interesting since the
antisense blocks its sense gene (SLC22A18, which acts as a tumor
suppressor) [24]. We thus speculated that the elevation of SLS22A18AS
Fig. 3. SLC22A18AS-mediated EMT and dissemination and their relevance to survival suppression. A: A quantitative real-time PCR analysis of the EMT marker
genes was performed in the stably expressed clone, GFP, or AS#3, which corresponds to GFP or SLC22A18AS gene. B: A549 parental cells and an A549 cell-based
stable trasnformant, AS#3 (each 5 × 105 cells, with Matrigel) were injected into the lungs of mice and maintained for 1 month. Left panel: Representative pho-
tographs of the transplanted cell-derived tumors in the resected lungs. The visible tumors are encircled by dotted lines and quantified by counting the tumor foci of the
resected lungs (right panel). C: Gene expression plots of SLC22A18AS from lung cancer specimens were obtained from a publicly available website (http://gepia.
cancer-pku.cn/). D: Overall survival plots according to SLC22A18AS expression levels were obtained from a publicly available website (http://kmplot.com/analysis/
). Data are mean ± SD. *p<0.05, ***p<0.001.
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might enhance cancer aggressiveness through the prevention of tumor
suppressive function(s) of its target sense.
The expression profiles of our six genes of interest were further
confirmed by the quantitative-real time PCR analysis results (Fig. 1C).
Of these six genes, we were particularly interested in SLC22A18AS
because it showed the highest expression rate in elevation among the
upregulated six genes, and there are only a few reports about its
function.
Because SPDEF transcriptional factor is a key mediator of NPTNβ-
triggered lung cancer dissemination, we first examined the relationship
between SPDEF and SLC22A18AS expression. As shown in Fig. 2A, we
observed that SPDEF has the ability to induce SLC22A18AS in
A549 cells. However, this induction rate was not comparable to that
caused by stable overexpression with NPTNβ (Fig. 1C), implying a
certain contribution of another NPTNβ-mediated pathway that may
orchestrate with SPDEF's functions to lead upregulation of SLC22A18AS
in transcriptional expression (Suppl. Fig. S6C).
To further test the antisense function that exerts a degradation of its
targeted-sense mRNA after complementary binding (like siRNA), we
next transiently forced the expression of foreign SLC22A18AS in
A549 cells. The expressed antisense in the transduced cells showed
markedly higher expression than that in the control GFP-delivered cells
(Fig. 2B). Under these conditions, we confirmed that the mRNA level of
the intrinsic SLC22A18 gene was markedly reduced. This result in-
dicates that SLC22A18AS works to bond with the complementary chain
of its sense mRNA (SLC22A18) as the antisense trait, leading to a
downregulation of SLC22A18.
We next examined the function(s) of SLC22A18AS coupled with the
downregulation of SLC22A18 in cancer behaviors such as cell growth,
migration, and invasion. Of interest, although the transient expression
of both sense and antisense of SLC22A18 showed no major differences
between them or when compared to that of the control GFP on the MTS-
based growth evaluation, we observed that the antisense expression
promoted either migration or invasion, whereas the sense expression
highly attenuated these cellular behaviors (Fig. 2C). The upregulation
of migration and invasion was also observed when we used the estab-
lished A549 clones (AS#1 and #3), which showed high expressions of
SLC22A18AS in a stable manner (Fig. 2D, middle and right panels).
The cell migration activity was further assessed by a more sophis-
ticated assay, the real-time cell mobility assay using the device EZ-
TAXIScan (ECI, Kawasaki, Japan), which provides multiple types of
information about the migrating cells together with cell morphology,
directionality, and velocity [25–27]. This additional analysis strength-
ened the former results, i.e., both of the AS clones showed markedly
high activities in both the directionality and the velocity of migration
compared to the activity of the control GFP clone (Suppl. Fig. S4A). The
growth was not affected in the AS clones.
This was also confirmed by another cell counting method (Fig. 2D,
left panel, Suppl. Fig. S4B). Both of the AS clones showed a slightly
decreased trend in this assay. These results suggest that SLC22A18AS
acts to enhance cancer migration and invasion processes but not
growth, and the level of SLC22A18AS represent cancer dissemination
through an inhibitory mechanism of its targeted sense mRNA.
Because cancer dissemination is triggered by an acquisition of the
EMT [28], we examined the possible linkage of SLC22A18AS and the
expression of the EMT phenotype in lung cancer cells. Phase contrast
microscopy revealed the appearance of morphological changes of the
SLC22A18AS clone AS#3 from the epithelial shape to a mesenchymal
fibroblast-like shape (Fig. 2E). This was not restricted to AS#3, as the
other clone AS#1 showed shapes that were similar to those of AS#3
(data not shown). The morphological change toward the mesenchymal
phenotype in clone AS#3 was confirmed by our evaluation of the cell-
shape-based quantification (Suppl. Fig. S5) as well as the expression of
several EMT markers (Fig. 3A).
A paper by Dey et al. [29] was of great help to us in conducting the
morphological assessment with a detailed and accurate quantification.
They used differential interference contrast (DIC) microscopy, which
provides a pseudo-3D (three-dimensional) image of the cell. By learning
their method and by using several other evaluation methods reviewed
by Kasprowicz et al. [30], we were eventually able to take advantage of
a simple enclosed method of cell examination that conveniently pro-
vides altered-cell shape information when combined with an ImageJ
analysis. With this approach, we observed that the cell morphology of
clone AS#3 was clearly changed compared to the cell morphology of
the parental cells, i.e., it showed a mesenchymal-like shape with an
extended area and extended major axis but not minor axis (Suppl. Fig.
S5). In addition, as shown in Fig. 3A, the expression of the epithelial
marker cadherin 1/E-cadherin (CDH1) was reduced and the expressions
of the following mesenchymal markers were increased in the AS#3
clone compared to their expression in the control GFP clone: CDH1,
vimentin (VIM), zinc finger E-box binding homeobox 2 (ZEB2), and
snail family transcriptional repressor 2/slug (SNAIL2).
Regarding the altered EMT genes, ZEB2 and SNAIL2 displayed
particularly high expression in the clone AS#3. This result is very in-
teresting for us since it was demonstrated that coupled ZEB2/SNAIL2
signaling plays a crucial role in EMT acquisition and the subsequent
disseminative metastasis of lung cancer [31]. There may be a close
relationship between ZEB2/SNAIL2-mediated EMT and metastatic dis-
semination, since we observed herein that clone AS#3 showed many
disseminated tumor foci compared to those from the parental
A549 cells in the lung when we inoculated them simultaneously into a
single site in individual mouse lungs, suggesting a highly disseminative
activity of the clone (Fig. 3B).
Under the in vivo conditions of the mouse model, we assessed the
EMT markers, ZEB1, ZEB2, SNAIL1 and SNAIL2, expression in the in-
jected cancer-derived nodules collected from the dissected whole lung
tissues (Suppl. Fig. S6A, left). It thus followed that AS#3-derived cancer
nodules show markedly higher expressions of ZEB2 and SNAIL2 than
those of the control GFP clone-derived cancer nodules (Suppl. Fig. S6A,
right). On the other hand, ZEB1 showed no any appreciable alteration in
expression between the two tumor specimens (GFP and AS#3) and
SNAIL1 was not detected in the both specimens.
To determine whether SPDEF regulates ZEB2 and SNAL2, we ex-
amined ZEB2 and SNAIL2 again in the SPDEF knockdown model of
clone A549-NPTNβ (a stable clone of A549 cells that shows persistent
overexpression of NPTNβ). Under the siRNA-mediated reduced ex-
pression of SPDEF at an efficient level, we observed that the expression
of ZEB2 was actually reduced, whereas SNAIL2 was not affected (Suppl.
Fig. S6B). Taken together, these findings led us to consider that SPDEF
mediates NPTNβ-triggered lung cancer dissemination through an
SLC22A18AS-ZEB2 axis. However, the role of SPDEF is controversial
since several studies indicated a cancer suppressive role of SPDEF in
prostate cancer [32,33] and colorectal cancer [34,35] (Suppl. Fig. S6C).
One possible explanation may arise different experimental settings and
different cell types that involve one or more regulator molecules and
the relevant pathways to regulate the expression and function of SPDEF.
This complex topic provides a new direction for our research.
For the assessment of the clinical importance of SLC22A18AS in
lung cancer, we next investigated the expression state of the gene and
its relevance to patient survival. Publicly available data were used in
these evaluations. The results of the expression analysis presented in
box plots (http://gepia.cancer-pku.cn/) showed highly elevated ex-
pressions of SLC22A18AS in patient-derived lung adenocarcinoma
specimens compared to the expression in healthy lung specimens
(Fig. 3C). In addition, Kaplan-Meier survival plots (http://kmplot.com/
analysis/) demonstrated that the patients with a high expression of
SLC22A18AS had lower overall survival compared to the patients with
a low expression (Fig. 3D). These results imply that the NPTNβ-medi-
ated upregulation of SLC22A18AS is a novel risk factor for the induc-
tion of metastasis, leading to poorer survival in lung cancer patients.
In light of our results, it appears that the SLC22A18AS-induced
disseminative activity that is concomitant with the EMT might be
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mediated by the prevention of its targeted sense SLC22A18. Thus,
SLC22A18 seems to function as a tumor suppressor, as was reported
[24]. However, it remains unknown how SLC22A18 suppresses the
EMT and cellular migration and invasion. SLC22A18 is one type of
membrane transporter, and it may regulate the uptake and pumping out
of one or more important molecules associated with cancer metastasis
and the EMT. The identification of such molecule(s) is part of our on-
going research.
It should also be determined whether SLC22A18AS has important
target molecule(s) other than SLC22A18 that may unexpectedly affect
cancer progression with the EMT and the subsequent cancer dis-
semination. However, we have not identified any reports about target
molecules of SLC22A18AS. In addition, unlike the case for miRNA, it is
too difficult to identify target molecules by searching for matched se-
quences on the basis of the SLC22A18AS sequence because of its great
length. Further comprehensive analyses of gene expression using cancer
cells that show up- or down-regulation of SLC22A18AS will help clarify
whether new target molecules associated with cancer exist.
In conclusion, our data indicate that SLC22A18AS is a key molecule
for the induction of the cancer EMT and the subsequent elevated cel-
lular motility that is potentially linked to high metastatic risk (Suppl.
Fig. S6C). The induction of the identified gene is regulated by the
S100A8/A9-NPTNβ-SPDEF axis that we identified, which greatly con-
tributes to lung cancer dissemination. However, SPDEF has contra-
dictory functions in cancer progression: one is cancer dissemination and
the other is cancer suppression. Our research has demonstrated that
NPTNβ regulates the expression of many molecules that include not
only SLC22A18AS but also previously reported cancer-relevant mole-
cules whose functions are tightly associating with EMT progression
such as FGFR4 [16], IGFBP2 [17,18], ITGA1 [19], ITGB4 [20,21], and
KLF5 [22,23] (Fig. 1C). We thus contemplate that these molecules may
affect the balance of SPDEF-mediated pathways, resulting in an en-
hancement of the cancer dissemination but not cancer suppression. We
hope that our results will help establish a preclinical method to target
this axis in order to further improve clinical responses and patient
survival. In fact, our newly developed biologics that block the inter-
action between S100A8/A9 and NPTNβ (as well as other receptors; e.g.,
EMMPRIN, RAGE, MCAM, and ALCAM) have prevented the metastasis
of melanoma and breast cancer [36,37].
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